{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-092735","form_type":"8-K","ticker":"RVMD","cik":"0001628171","company_name":"Revolution Medicines, Inc.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.864709+00:00","generated_at":"2026-05-31T11:47:30.666099+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Revolution Medicines Q2 net loss $133M; advances RMC-6236 toward Phase 3 in PDAC","bullets":["Q2 net loss $133.2M vs $98.3M YoY; revenue zero due to Sanofi collaboration termination.","Cash $1.59B; projects funding into 2027; FY 2024 GAAP net loss guidance $560-600M.","RMC-6236 in PDAC: median PFS 8.1 months (KRAS G12X); Phase 3 RASolute 302 planned for 2L this year.","Board appoints Frank Clyburn, former Merck Keytruda leader; new senior hires in medical affairs.","R&D expenses $134.9M vs $98.0M; G&A $21.7M vs $14.6M, driven by clinical and commercial prep."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-092735","json":"https://secwatch.observer/filing/0000950170-24-092735.json","markdown":"https://secwatch.observer/filing/0000950170-24-092735.md","text":"https://secwatch.observer/filing/0000950170-24-092735.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1628171/000095017024092735/0000950170-24-092735-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1628171/000095017024092735/rvmd-20240805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:47:30.666099+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"60df6ae4ac","claim":"Frank K. Clyburn, Jr. was appointed as Director at Revolution Medicines, Inc..","evidence_excerpt":"On August 5, 2024, the board of directors (the “Board”) of the Company increased the authorized size of the Board to ten directors and appointed Frank K. Clyburn, Jr. as a member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1628171/000095017024092735/0000950170-24-092735-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}